AbbVie Reports 10.3 Percent Revenue Growth in Q3 2026

Pharmaceutical manufacturer AbbVie reported $17.4 billion in third-quarter 2026 revenue, meeting Wall Street expectations as sales increased 10.3 percent year over year. The company's adjusted earnings exceeded analyst estimates, while management raised its full-year earnings guidance amid continued growth across its product portfolio.

According to S&P analyst consensus estimates, quarterly revenue reached $17.4 billion, compared with expectations of $17.34 billion. Adjusted earnings totaled $3.82 per share, surpassing the $3.77 consensus estimate by 1.3 percent.

AbbVie also reported an operating margin of 36 percent, compared with 12.1 percent in the same quarter last year. The company raised and narrowed its full-year adjusted earnings guidance, setting the midpoint at $13.97 per share.

Robert A. Michael, chairman and chief executive officer of AbbVie, attributed the results to execution across the company's business portfolio and developments supporting its long-term growth strategy.

"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert A. Michael, chairman and chief executive officer of AbbVie.

Michael also highlighted regulatory approvals, clinical developments and the company's acquisition of Apogee Therapeutics as important elements of its growth strategy.

"We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend." said Robert A. Michael, chairman and chief executive officer of AbbVie.

Longer-term revenue trends show a different growth trajectory. According to the financial analysis published by Yahoo Finance, AbbVie recorded a compounded annual revenue growth rate of 3.7 percent over the previous five years.

However, more recent performance has been stronger. The company's annualized revenue growth reached 9 percent over the past two years, exceeding its five-year historical rate.

For the next 12 months, S&P sell-side analyst estimates project revenue growth of 8.8 percent. That forecast is broadly consistent with AbbVie's recent two-year growth rate.

AbbVie's market capitalization stood at $513.9 billion. Its third-quarter results combined revenue growth, higher adjusted earnings and an improved operating margin, while management also announced an increase in the quarterly dividend.